X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GLENMARK PHARMA VENUS REMEDIES/
GLENMARK PHARMA
 
P/E (TTM) x -898.2 14.3 - View Chart
P/BV x 0.3 3.8 7.0% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 VENUS REMEDIES   GLENMARK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
GLENMARK PHARMA
Mar-17
VENUS REMEDIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs218993 22.0%   
Low Rs82729 11.3%   
Sales per share (Unadj.) Rs365.6325.5 112.3%  
Earnings per share (Unadj.) Rs1.539.3 3.8%  
Cash flow per share (Unadj.) Rs37.948.7 77.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs382.5159.2 240.3%  
Shares outstanding (eoy) m11.44282.17 4.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.42.6 15.5%   
Avg P/E ratio x101.021.9 460.7%  
P/CF ratio (eoy) x4.017.7 22.4%  
Price / Book Value ratio x0.45.4 7.3%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m1,717242,991 0.7%   
No. of employees `0001.013.0 7.9%   
Total wages/salary Rs m32416,408 2.0%   
Avg. sales/employee Rs Th4,100.77,083.9 57.9%   
Avg. wages/employee Rs Th318.01,265.4 25.1%   
Avg. net profit/employee Rs Th16.7855.1 1.9%   
INCOME DATA
Net Sales Rs m4,18391,857 4.6%  
Other income Rs m20374 5.4%   
Total revenues Rs m4,20392,230 4.6%   
Gross profit Rs m81220,367 4.0%  
Depreciation Rs m4172,644 15.8%   
Interest Rs m3802,373 16.0%   
Profit before tax Rs m3515,724 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m183,827 0.5%   
Profit after tax Rs m1711,088 0.2%  
Gross profit margin %19.422.2 87.5%  
Effective tax rate %51.624.3 211.9%   
Net profit margin %0.412.1 3.4%  
BALANCE SHEET DATA
Current assets Rs m2,77168,746 4.0%   
Current liabilities Rs m1,93127,027 7.1%   
Net working cap to sales %20.145.4 44.2%  
Current ratio x1.42.5 56.4%  
Inventory Days Days12585 147.1%  
Debtors Days Days5496 56.3%  
Net fixed assets Rs m5,32824,132 22.1%   
Share capital Rs m114282 40.5%   
"Free" reserves Rs m4,17744,643 9.4%   
Net worth Rs m4,37644,925 9.7%   
Long term debt Rs m1,91145,363 4.2%   
Total assets Rs m8,428117,639 7.2%  
Interest coverage x1.17.6 14.3%   
Debt to equity ratio x0.41.0 43.2%  
Sales to assets ratio x0.50.8 63.6%   
Return on assets %4.711.4 41.1%  
Return on equity %0.424.7 1.6%  
Return on capital %6.619.1 34.5%  
Exports to sales %00-   
Imports to sales %20.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m858NA-   
Fx inflow Rs m056,152 0.0%   
Fx outflow Rs m8588,084 10.6%   
Net fx Rs m-85848,068 -1.8%   
CASH FLOW
From Operations Rs m4696,574 7.1%  
From Investments Rs m29-7,124 -0.4%  
From Financial Activity Rs m-4645,432 -8.5%  
Net Cashflow Rs m351,992 1.7%  

Share Holding

Indian Promoters % 32.9 48.3 68.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.6%  
FIIs % 0.6 34.4 1.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 56,727 35.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  PFIZER  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 16, 2018 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS